Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Cardiology
Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators In The Cardiovascular Research Network, Robert T. Greenlee, Alan S. Go, Pamela N. Peterson, Andrea E. Cassidy-Bushrow, Charles Gaber, Romel Garcia-Montilla, Alan H. Kadish
Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators In The Cardiovascular Research Network, Robert T. Greenlee, Alan S. Go, Pamela N. Peterson, Andrea E. Cassidy-Bushrow, Charles Gaber, Romel Garcia-Montilla, Alan H. Kadish
Office of the President Publications and Research
BACKGROUND: Primary prevention implantable cardioverter-defibrillators (ICDs) reduce mortality in selected patients with left ventricular systolic dysfunction by delivering therapies (antitachycardia pacing or shocks) to terminate potentially lethal arrhythmias; inappropriate therapies also occur. We assessed device therapies among adults receiving primary prevention ICDs in 7 healthcare systems.
METHODS AND RESULTS: We linked medical record data, adjudicated device therapies, and the National Cardiovascular Data Registry ICD Registry. Survival analysis evaluated therapy probability and predictors after ICD implant from 2006 to 2009, with attention to Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups: left ventricular ejection fraction, 31% to 35%; …